Pfizer Inc. Stock

It was a rock star during the coronavirus pandemic, but Pfizer (NYSE: PFE) hasn't been the most exciting company in 2024. Its stock has become something of a value play, at least according to one

Investing $5,000 in the stock market can be a significant amount of money if you keep it invested for the very long haul. Suppose you find a good growth stock that rises by an average of 15% over a

Though the S&P 500 dipped earlier this month, it's important to keep in mind that we're still in a very positive market environment. The bull market is going strong, with the benchmark rising 17% so

The stock market has been on fire this year, but much of that performance can be attributed to a handful of tech giants that have a disproportionate weight of the S&P 500 and are benefiting from the

There are a million and one ways to make a buck on Wall Street, but some methods are more reliable than others. If you're an investor looking for a way to beef up your passive income stream or you

I've kicked myself for not buying a stock sooner more times than I'd like to admit. Even worse are the stocks I should have bought but never did. If you invest long enough, you'll no doubt feel the

Shares of beleaguered drug store and pharmacy chain Walgreens Boots Alliance (NASDAQ: WBA) fell 8.4% on Tuesday as of 3:22 p.m. ET.

The reason for the drop today appears to be twofold: One, Pfizer

With Pfizer (NYSE: PFE) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear

Dividend stocks can be a great source of cash flow for your portfolio. You don't need to settle for stocks that pay just a few percentage points, either. Some fairly safe, high-yielding stocks pay

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently fell behind in their race with Moderna (NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line

Pharmaceutical giant Pfizer (NYSE: PFE) has been in a bit of a freefall since early 2022, with shares down by 46%. Pfizer's revenue and earnings dropped off a cliff along with its

In the thick of the coronavirus pandemic several years ago, any positive news from a developer of COVID-19 vaccines or drugs would have been met with a surge of buying in its stock. We're not in

The market is a bit jittery right now thanks to a confluence of factors, including a weaker-than-anticipated U.S. jobs report, international geopolitical issues, and foreign currency disruptions --

Would you like to improve your passive income stream but don't have a lot of extra cash to throw around? If so, I have great news: These days, $100 is all it takes to acquire a share of three top

While the COVID-19 pandemic is an increasingly distant memory for most investors, Pfizer (NYSE: PFE) has struggled to move past the overhang of record vaccine sales and earnings in 2021 and 2022

Demand for COVID-19 vaccines and drugs has been fading for a while now. And that has put a big dent in Pfizer's (NYSE: PFE) sales and profit numbers. On top of that, the stock is also facing

The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%

Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro

Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of

Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.

However, the

The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are

Just a couple of years ago, Pfizer's (NYSE: PFE) revenue was soaring thanks to sales of its coronavirus vaccine. In fact, the vaccine became the world's best-selling pharmaceutical product and even

Image source: The Motley Fool.

Pfizer (NYSE: PFE)Q2 2024 Earnings CallJul 30, 2024, 10:30 a.m. ET

Operator

Continue reading

Source Fool.com

Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products

If you're looking to invest in order to get richer, that's great -- because most of us need to be amassing a war chest for retirement (not to mention other financial goals, such as a down payment